---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005160"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:17:12.663905+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+

## Summary
- Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.
- ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.
- RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.
- Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.
- Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B.

## SEC filing metadata
- accession: 0001193125-25-005160
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/0001193125-25-005160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/d900352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005160
- JSON: https://secwatch.observer/filing/0001193125-25-005160.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.